

Press release
4 February 2009
Göteborg

Announcement of offer document in relation to the offer for MediCult

On 14 January 2009, Vitrolife AB (publ) ("Vitrolife") announced its intention to make a voluntary offer to the shareholders of MediCult a/s ("MediCult") to acquire all outstanding shares in MediCult for consideration in the form of new shares in Vitrolife (the "Offer").

The offer document in relation to the Offer is now available on www.vitrolife.com and www.carnegie.no and may also be obtained from Carnegie ASA, telephone number +47 22 00 93 00, or Vitrolife, telephone number +46 31 721 80 00.

The offer document is available in English and is also intended to form the basis for the admission to trading on NASDAQ OMX Stockholm of the new Vitrolife shares following completion of the Offer.

This announcement is not for distribution or transmission, directly or indirectly, into or in the United States, Canada, Australia, Japan or the Republic of South Africa and does not constitute, or form part of, an offer to purchase, sell, exchange or subscribe for or the solicitation of an offer to purchase, sell, exchange or subscribe for any securities of Vitrolife or MediCult to any person in the United States, Canada, Australia, Japan or the Republic of South Africa or in any other jurisdiction in which the making of the Offer or the acceptance of any tender of shares therein would not be made in compliance with the laws of such jurisdiction, nor the solicitation of any vote or approval in any such jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. The Offer will not be made, directly or indirectly, into or in the United States, Canada, Australia, Japan or the Republic of South Africa or any other jurisdiction where doing so would constitute a violation of the laws of such jurisdiction or would require registration of or approval of an offer document (other than Norway), or by use of the mails, or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the Internet) of interstate or foreign commerce, or of any facility of a national securities exchange, of the United States, Canada, Australia, Japan or the Republic of South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility or from within any such jurisdiction. The new Vitrolife shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of new Vitrolife shares is being made in the United States.

February 4, 2009

Magnus Nilsson
CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

Vitrolife is required under the Swedish Securities Market Act to publish the information in this press release. The information was submitted for publication on 4 February 2009 at 8:00 am CET.